Industry, stakeholders push on EU trial times
TheCouncil of the European Union must preserve the competitive timelinesfor assessment set out in the European Commission’s proposedregulation on clinical trials if it wants to keep Europe at thecutting edge of biopharmaceutical innovation, a coalition ofpharmaceutical and biotechnology industry associations, researchersand patient groups insists.
Read More




